Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 710

1.

Retinopathy of prematurity in the United Kingdom: retreatment rates, visual and structural 1-year outcomes.

Adams GG, Bunce C, Xing W, Butler L, Long V, Reddy A, Dahlmann-Noor AH; UK Retinopathy of Prematurity Special Interest Group.

Eye (Lond). 2018 Jul 16. doi: 10.1038/s41433-018-0151-y. [Epub ahead of print]

PMID:
30013158
2.

Intravitreal Fluocinolone Acetonide (ILUVIEN) Implant for the Treatment of Refractory Cystoid Macular Oedema After Retinal Detachment Repair.

Alfaqawi F, Sarmad A, Ayesh K, Mitra A, Sharma A.

Turk J Ophthalmol. 2018 Jun;48(3):155-157. doi: 10.4274/tjo.34966. Epub 2018 Jun 28.

3.

The Role of Histone Deacetylase Inhibitors in Uveal Melanoma: Current Evidence.

Moschos MM, Dettoraki M, Androudi S, Kalogeropoulos D, Lavaris A, Garmpis N, Damaskos C, Garmpi A, Tsatsos M.

Anticancer Res. 2018 Jul;38(7):3817-3824. doi: 10.21873/anticanres.12665. Review.

PMID:
29970501
4.

Outcome of fixed volume intracameral sodium hyaluronate 1.4% injection for early postoperative hypotony after Baerveldt glaucoma implant.

Chiam PJ, Chen X, Haque MS, Sung VC.

Clin Exp Ophthalmol. 2018 Jun 22. doi: 10.1111/ceo.13347. [Epub ahead of print]

PMID:
29934963
5.

Reversible retinal toxicity in early oral Entecavir therapy for hepatitis-B infection.

Pilli S, Lip PL.

Eye (Lond). 2018 Jun 22. doi: 10.1038/s41433-018-0156-6. [Epub ahead of print] No abstract available.

PMID:
29934633
6.

Efficacy of Botulinum Toxin in the Treatment of Convergence Spasm.

Gupta S, Gan J, Jain S.

Strabismus. 2018 Sep;26(3):122-125. doi: 10.1080/09273972.2018.1483952. Epub 2018 Jun 12.

PMID:
29894224
7.

mTOR-inhibiting pharmacotherapy for the treatment of non-infectious uveitis: a systematic review protocol.

Blair J, Barry R, Murray PI, Moore DJ, Denniston AK.

Syst Rev. 2018 Jun 9;7(1):83. doi: 10.1186/s13643-018-0745-2.

8.

Bilateral extensive multiple multi-layered retinal haemorrhage in a patient with alcoholic liver disease.

Elaraoud I, Damato E.

Pan Afr Med J. 2018 Jan 30;29:89. doi: 10.11604/pamj.2018.29.89.10869. eCollection 2018. No abstract available.

9.

Cerebrospinal fluid immunoglobulin light chain ratios predict disease progression in multiple sclerosis.

Rathbone E, Durant L, Kinsella J, Parker AR, Hassan-Smith G, Douglas MR, Curnow SJ.

J Neurol Neurosurg Psychiatry. 2018 May 9. pii: jnnp-2018-317947. doi: 10.1136/jnnp-2018-317947. [Epub ahead of print]

10.

Neurotrophic keratopathy.

Dua HS, Said DG, Messmer EM, Rolando M, Benitez-Del-Castillo JM, Hossain PN, Shortt AJ, Geerling G, Nubile M, Figueiredo FC, Rauz S, Mastropasqua L, Rama P, Baudouin C.

Prog Retin Eye Res. 2018 Apr 23. pii: S1350-9462(17)30121-0. doi: 10.1016/j.preteyeres.2018.04.003. [Epub ahead of print] Review.

PMID:
29698813
11.

Phase I Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis.

Bonini S, Lambiase A, Rama P, Filatori I, Allegretti M, Chao W, Mantelli F; REPARO Study Group.

Ophthalmology. 2018 Apr 10. pii: S0161-6420(17)33805-8. doi: 10.1016/j.ophtha.2018.03.004. [Epub ahead of print] No abstract available.

12.

Phase 2 Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis.

Bonini S, Lambiase A, Rama P, Sinigaglia F, Allegretti M, Chao W, Mantelli F; REPARO Study Group.

Ophthalmology. 2018 Apr 10. pii: S0161-6420(17)31993-0. doi: 10.1016/j.ophtha.2018.02.022. [Epub ahead of print]

13.

Time to regenerate: the doctor in the age of artificial intelligence.

Liu X, Keane PA, Denniston AK.

J R Soc Med. 2018 Apr;111(4):113-116. doi: 10.1177/0141076818762648. No abstract available.

PMID:
29648509
14.

Central serous chorioretinopathy with angioid streaks: a rare combination.

Sarmad A, Alfaqawi F, Chakrabarti M, Elsherbiny S.

GMS Ophthalmol Cases. 2018 Feb 22;8:Doc01. doi: 10.3205/oc000083. eCollection 2018.

15.

Determinants of Outcomes of Adenoviral Keratoconjunctivitis.

Lee CS, Lee AY, Akileswaran L, Stroman D, Najafi-Tagol K, Kleiboeker S, Chodosh J, Magaret A, Wald A, Van Gelder RN; BAYnovation Study Group.

Ophthalmology. 2018 Mar 27. pii: S0161-6420(17)32895-6. doi: 10.1016/j.ophtha.2018.02.016. [Epub ahead of print]

PMID:
29602567
16.

Valsalva maculopathy: To treat or not to treat.

Mukherjee C, Kumar A, Mitra A.

Oman J Ophthalmol. 2018 Jan-Apr;11(1):78-81. doi: 10.4103/ojo.OJO_91_2016.

17.

Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years.

Fusi-Rubiano W, Mukherjee C, Lane M, Tsaloumas MD, Glover N, Kidess A, Denniston AK, Palmer HE, Manna A, Morjaria R.

BMC Ophthalmol. 2018 Feb 27;18(1):62. doi: 10.1186/s12886-018-0726-1.

18.

Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry.

Dumusc A, Ng WF, James K, Griffiths B, Price E, Pease C, Emery P, Lanyon P, Jones A, Bombardieri M, Sutcliffe N, Pitzalis C, Gupta M, McLaren J, Cooper A, Giles I, Isenberg D, Saravanan V, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots R, Gendi N, Akil M, Barone F, Fisher B, Rauz S, Richards A, Bowman S.

Swiss Med Wkly. 2018 Feb 7;148:w14588. doi: 10.4414/smw.2018.14588. eCollection 2018.

19.

Re: Schlenker et al.: Efficacy, safety, and risk factors for failure of standalone ab interno gelatin microstent implantation versus standalone trabeculectomy (Ophthalmology. 2017;124:1579-1588).

Masood I, Sigona M, Pajaujis M.

Ophthalmology. 2018 Feb;125(2):e16-e17. doi: 10.1016/j.ophtha.2017.09.011. No abstract available.

PMID:
29389415
20.

Optimizing OCT acquisition parameters for assessments of vitreous haze for application in uveitis.

Montesano G, Way CM, Ometto G, Ibrahim H, Jones PR, Carmichael R, Liu X, Aslam T, Keane PA, Crabb DP, Denniston AK.

Sci Rep. 2018 Jan 26;8(1):1648. doi: 10.1038/s41598-018-20092-y.

Supplemental Content

Loading ...
Support Center